Interestingly, a recent study showed that tumor-targeting antibodies, such as cetuximab or trastuzumab, induced the upregulation of 4-1BB on NK cells and, when NK cells were stimulated with an agonist 4-1BB antibody, they exhibited an improved cytotoxicity against cancer cells [87]. This evidence concerns the gene TNFRSF9 and neoplasm.